Generon Aiming High As It Progresses IL-22 Therapy
This article was originally published in PharmAsia News
China’s Generon says it is the first company to develop an IL-22-targeting biologic for multiple therapeutic indications such as acute pancreatitis, acute alcoholic hepatitis and GvHD. With the project now entering Phase II trials in the US, the firm is seeking global licensing and collaboration opportunities and is open to fundraising from venture capital and strategic investors to support development.
You may also be interested in...
Continuing with a double-digit growth rate, China remained a leading driver for Sanofi’s global business in the fourth quarter. Going digital and building local partnerships emerged as key themes for Sanofi China to explore more opportunities, although it may face testing problems for its vaccine business in the country.
Oncologie acquires PS-targeting candidate bavituximab, which may help other cancer therapies in attacking tumors. BridgeBio's newest spinout will develop former Novartis cancer candidate infigratinib.
Strongbridge obtains rights from AEterna Zentaris to first drug approved for adult growth hormone deficiency. While the J.P. Morgan Healthcare Conference didn't have many major deal announcements, there was a flurry of announcements around discovery and development capabilities.